Article: Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon

In a controlled double blind trial the symptomatic effect of the calcium channel blocker nisoldipine was assessed in 19 patients with idiopathic Raynaud's phenomenon. Nisoldipine significantly reduced the frequency of attacks (p less than 0.05), whilst having a non-significant tendency (p less than 0.10) to reduce the severity of attacks. Side-effects were uncommon. It is concluded that nisoldipine is a promising agent for the symptomatic treatment of idiopathic Raynaud's phenomenon.

Citing Articles

Beneficial Extracardiac Effects of Cardiovascular Medications.

Butt A, Patel J, Shirwany H, Mirza Q, Hoover J, Khouzam R Curr Cardiol Rev. 2021; 18(2):e151021197270.

PMID: 34779371 PMC: 9413730. DOI: 10.2174/1573403X17666211015145132.

Calcium channel blockers for primary and secondary Raynaud's phenomenon.

Rirash F, Tingey P, Harding S, Maxwell L, Tanjong Ghogomu E, Wells G Cochrane Database Syst Rev. 2017; 12:CD000467.

PMID: 29237099 PMC: 6486273. DOI: 10.1002/14651858.CD000467.pub2.

Calcium channel blockers for primary Raynaud's phenomenon.

Ennis H, Hughes M, Anderson M, Wilkinson J, Herrick A Cochrane Database Syst Rev. 2016; 2:CD002069.

PMID: 26914257 PMC: 7065590. DOI: 10.1002/14651858.CD002069.pub5.

The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study.

Brown K, Middaugh S, Haythornthwaite J, Bielory L J Behav Med. 2001; 24(2):137-53.

PMID: 11392916 DOI: 10.1023/a:1010758530555.

Nisoldipine in primary Raynaud's phenomenon.

Challenor V, Waller D, Francis D, Francis J, Mani R, Roath S Eur J Clin Pharmacol. 1987; 33(1):27-30.

PMID: 3691593 DOI: 10.1007/BF00610375.

References

1.

Smith C, McKendry R . Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet. 1982; 2(8311):1299-301. DOI: 10.1016/s0140-6736(82)91508-2. View

2.

Winston E, Pariser K, Miller K, Salem D, Creager M . Nifedipine as a therapeutic modality for Raynaud's phenomenon. Arthritis Rheum. 1983; 26(10):1177-80. DOI: 10.1002/art.1780261001. View

3.

Antman E, Stone P, Muller J, Braunwald E . Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med. 1980; 93(6):875-85. DOI: 10.7326/0003-4819-93-6-875. View

4.

Creager M, Pariser K, Winston E, Rasmussen H, Miller K, COFFMAN J . Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon. Am Heart J. 1984; 108(2):370-3. DOI: 10.1016/0002-8703(84)90627-6. View

5.

Olsen N, Nielsen S . Prevalence of primary Raynaud phenomena in young females. Scand J Clin Lab Invest. 1978; 38(8):761-4. DOI: 10.1080/00365517809104884. View

6.

Gjorup T, Kelbaek H, Hartling O, Nielsen S . Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J. 1986; 111(4):742-5. DOI: 10.1016/0002-8703(86)90109-2. View

7.

Porter J, Rivers S, Anderson C, Baur G . Evaluation and management of patients with Raynaud's syndrome. Am J Surg. 1981; 142(2):183-9. DOI: 10.1016/0002-9610(81)90272-5. View

8.

Nilsson H, Jonasson T, Ringqvist I . Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine. Acta Med Scand. 1984; 215(2):135-9. DOI: 10.1111/j.0954-6820.1984.tb04983.x. View

9.

Rodeheffer R, Rommer J, Wigley F, Smith C . Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med. 1983; 308(15):880-3. DOI: 10.1056/NEJM198304143081507. View

10.

Halperin J, COFFMAN J . Pathophysiology of Raynaud's disease. Arch Intern Med. 1979; 139(1):89-92. View

11.

Kinney E, Nicholas G, Gallo J, Pontoriero C, Zelis R . The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol. 1982; 22(1):74-6. DOI: 10.1002/j.1552-4604.1982.tb05712.x. View

12.

Ettinger W, Wise R, Schaffhauser D, Wigley F . Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med. 1984; 77(3):451-6. DOI: 10.1016/0002-9343(84)90101-3. View

Controlled Double Blind Trial of Nisoldipine in the Treatment of Idiopathic Raynaud's Phenomenon